JP2012500232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012500232A5 JP2012500232A5 JP2011523312A JP2011523312A JP2012500232A5 JP 2012500232 A5 JP2012500232 A5 JP 2012500232A5 JP 2011523312 A JP2011523312 A JP 2011523312A JP 2011523312 A JP2011523312 A JP 2011523312A JP 2012500232 A5 JP2012500232 A5 JP 2012500232A5
- Authority
- JP
- Japan
- Prior art keywords
- stereoisomer
- proportions
- pharmaceutically usable
- mixture
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 25
- 239000000203 mixture Substances 0.000 description 20
- 150000003839 salts Chemical class 0.000 description 19
- -1 COOA Chemical group 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 241001274216 Naso Species 0.000 description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 1
- 206010067953 Radiation fibrosis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000005661 deetherification reaction Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008038220A DE102008038220A1 (de) | 2008-08-18 | 2008-08-18 | Oxadiazolderivate |
| DE102008038220.5 | 2008-08-18 | ||
| PCT/EP2009/004992 WO2010020305A1 (de) | 2008-08-18 | 2009-07-09 | Oxadiazolderivate für die behandlung von diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012500232A JP2012500232A (ja) | 2012-01-05 |
| JP2012500232A5 true JP2012500232A5 (https=) | 2012-08-30 |
| JP5571665B2 JP5571665B2 (ja) | 2014-08-13 |
Family
ID=41010866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523312A Expired - Fee Related JP5571665B2 (ja) | 2008-08-18 | 2009-07-09 | 糖尿病を処置するためのオキサジアゾール誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8377975B2 (https=) |
| EP (1) | EP2313380B1 (https=) |
| JP (1) | JP5571665B2 (https=) |
| AU (1) | AU2009284453B2 (https=) |
| CA (1) | CA2734397C (https=) |
| DE (1) | DE102008038220A1 (https=) |
| ES (1) | ES2444129T3 (https=) |
| IL (1) | IL211267A (https=) |
| WO (1) | WO2010020305A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013063458A2 (en) * | 2011-10-27 | 2013-05-02 | Mayo Foundation For Medical Education And Research | Inhibiting g protein coupled receptor 6 kinase polypeptides |
| DE102013226711A1 (de) * | 2013-12-19 | 2015-06-25 | Beiersdorf Ag | Verwendung von Alkylamidothiazolen in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut |
| EP3134399A4 (en) | 2014-04-21 | 2017-12-27 | Mayo Foundation for Medical Education and Research | Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides |
| CA3072103A1 (en) * | 2017-08-21 | 2019-02-28 | Microbiotix, Inc. | Metabolically stable n-acylaminooxadiazoles useful as antibacterial agents |
| US11447482B1 (en) | 2019-02-14 | 2022-09-20 | KUDA Therapeutics, Inc. | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE35261C (de) | FIRMA CARL UHL & CO. in Braunschweig | Neuerung an Stimmschrauben | ||
| DD35261A1 (de) * | 1962-08-31 | 1965-02-15 | Verfahren zur Herstellung von 5-substituierten 2-Amino-1,3,4-oxdiazolen | |
| US3790588A (en) | 1969-10-24 | 1974-02-05 | Gulf Research Development Co | Method of manufacturing dialkylamino-1,3,4-oxadiazoles and 1,3,4-thiadiazoles |
| NZ227841A (en) | 1988-02-12 | 1991-08-27 | Merck Sharp & Dohme | Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions |
| US5256680A (en) * | 1988-11-29 | 1993-10-26 | Warner-Lambert Company | 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents |
| NZ231534A (en) * | 1988-11-29 | 1992-02-25 | Warner Lambert Co | 3,5-di-t-butyl-4-hydroxyphenyl-triazoles, oxadiazoles and thiadiazoles; anti-inflammatory compositions |
| US5155122A (en) * | 1988-11-29 | 1992-10-13 | Warner-Lambert Company | 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents |
| DE19917990A1 (de) | 1999-04-20 | 2000-11-02 | Florian Lang | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
| DE10042137A1 (de) | 2000-08-28 | 2002-03-14 | Florian Lang | sgk2 und sgk3 als diagnostische und therapeutische Targets |
| US6951848B2 (en) | 2001-03-12 | 2005-10-04 | Millennium Pharmaceuticals, Inc., | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| US20030108403A1 (en) | 2001-12-14 | 2003-06-12 | Scoyoc James E. Van | Fluid flow bolt system |
| WO2003051847A1 (en) | 2001-12-19 | 2003-06-26 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| JP4751063B2 (ja) | 2002-05-17 | 2011-08-17 | ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ | キナーゼ阻害剤として活性のアミノインダゾール誘導体、それらの調製方法、及びそれらを含む薬学的組成物 |
| WO2004052280A2 (en) | 2002-12-10 | 2004-06-24 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
| US20050019366A1 (en) | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
| WO2005000813A1 (en) | 2003-05-30 | 2005-01-06 | Imclone Systems Incorporated | Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7569578B2 (en) | 2003-12-05 | 2009-08-04 | Bristol-Meyers Squibb Company | Heterocyclic anti-migraine agents |
| CN1886686A (zh) | 2003-12-24 | 2006-12-27 | 皮雷利&C.有限公司 | 低损耗微环形谐振器设备 |
| WO2005105788A1 (en) | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
| US7531556B2 (en) * | 2004-04-28 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| PL382308A1 (pl) * | 2004-08-25 | 2007-08-20 | Targegen, Inc. | Związki heterocykliczne i sposoby stosowania |
| EA012181B1 (ru) | 2004-10-18 | 2009-08-28 | Амген, Инк. | Соединения тиадиазола и их применение |
| US7795283B2 (en) | 2004-12-14 | 2010-09-14 | Astrazeneca Ab | Oxadiazole derivative as DGAT inhibitors |
| WO2006064375A2 (en) | 2004-12-16 | 2006-06-22 | Ab Science | Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases |
| KR20080080584A (ko) | 2005-11-30 | 2008-09-04 | 버텍스 파마슈티칼스 인코포레이티드 | ｃ-Ｍｅｔ의 억제제 및 이의 용도 |
| HUE030390T2 (en) | 2005-12-21 | 2017-05-29 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
| JP2009538899A (ja) | 2006-05-30 | 2009-11-12 | ファイザー・プロダクツ・インク | トリアゾロピリダジン誘導体 |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| DE102006048728A1 (de) * | 2006-10-16 | 2008-04-17 | Merck Patent Gmbh | 3-Amino-imidazo{1,2-a]pyridinderivate |
| CA2667453A1 (en) | 2006-10-23 | 2008-05-02 | Sgx Pharmaceuticals, Inc. | Triazolo-pyridazine protein kinase modulators |
| EP1939187A1 (en) | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
| DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
-
2008
- 2008-08-18 DE DE102008038220A patent/DE102008038220A1/de not_active Withdrawn
-
2009
- 2009-07-09 WO PCT/EP2009/004992 patent/WO2010020305A1/de not_active Ceased
- 2009-07-09 CA CA2734397A patent/CA2734397C/en not_active Expired - Fee Related
- 2009-07-09 AU AU2009284453A patent/AU2009284453B2/en not_active Ceased
- 2009-07-09 EP EP09777077.0A patent/EP2313380B1/de not_active Not-in-force
- 2009-07-09 ES ES09777077.0T patent/ES2444129T3/es active Active
- 2009-07-09 JP JP2011523312A patent/JP5571665B2/ja not_active Expired - Fee Related
- 2009-07-09 US US13/059,079 patent/US8377975B2/en not_active Expired - Fee Related
-
2011
- 2011-02-17 IL IL211267A patent/IL211267A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6132850B2 (ja) | グリタゾンおよびｎｒｆ２アクチベーターを含む医薬組成物 | |
| JP2012500232A5 (https=) | ||
| CN101600683B (zh) | 治疗性化合物 | |
| JP2010532768A5 (https=) | ||
| JP2019531320A5 (https=) | ||
| RU2012142180A (ru) | Ингибиторы катехол-о-метилтрансферазы и их применение для лечения психотических расстройств | |
| JP2011530545A5 (https=) | ||
| SI2303270T1 (en) | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | |
| JP2012521429A5 (https=) | ||
| TW200836715A (en) | Novel composition for treating metabolic syndrome | |
| JP2010529051A5 (https=) | ||
| JP2011519876A5 (https=) | ||
| JP2013521286A5 (https=) | ||
| JP2008536875A (ja) | ビス（チオヒドラジド）アミド化合物による併用癌療法 | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2013508279A5 (https=) | ||
| CN1846699A (zh) | 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用 | |
| RU2012158142A (ru) | Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации | |
| JP2015522547A5 (https=) | ||
| JP2017141277A5 (https=) | ||
| JP2013532668A5 (https=) | ||
| WO2006113572A1 (en) | Methods of increasing natural killer cell activity for therapy | |
| JP2014505107A5 (https=) | ||
| CN110169962A (zh) | 用于治疗癌症的氧烯洛尔组合物 | |
| JP2011046708A5 (https=) |